Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Strides Pharma Science Limited (STAR.NS)
Bengaluru, IN
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.03% | -1.66% | +14.57% | +31.28% | +27.56% | +26.81% | +65.86% | +564.59% | +201.26% | +135.97% | +183.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.6% ★ Q1'26: +11.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+37.0% ★ Q1'26: +54.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.2% ★ Q1'26: +18.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.9% ★ Q1'26: +14.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+13.2% ★ Q1'26: +13.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.2% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.90× Q1'26: 1.83× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.96B
est: 12.15B (-1.6%)
|
28.62B
est: 32.13B (-10.9%)
|
27.55B
est: 38.00B (-27.5%)
|
28.45B
est: 32.63B (-12.8%)
|
21.20B
est: 30.55B (-30.6%)
|
26.83B
est: 28.92B (-7.2%)
|
32.80B
est: 32.81B (0.0%)
|
30.59B
est: 30.71B (-0.4%)
|
36.68B
est: 37.60B (-2.4%)
|
38.28B
est: 42.09B (-9.0%)
|
44.75B
est: 46.29B (-3.3%)
|
48.28B
47.94B – 48.62B
+4.3% YoY
|
57.61B
56.41B – 58.82B
+19.3% YoY
|
68.26B
65.62B – 70.91B
+18.5% YoY
|
| EBITDA |
2.41B
est: 1.50B (+60.8%)
|
4.19B
est: 26.55B (-84.2%)
|
5.30B
est: 2.45B (+116.1%)
|
4.06B
est: 5.40B (-24.9%)
|
1.98B
est: 7.29B (-72.8%)
|
3.58B
est: 3.48B (+2.9%)
|
5.17B
est: 181.83M (+2,741.4%)
|
-214.95M
est: 210.45M (-202.1%)
|
3.66B
est: 221.76M (+1,551.2%)
|
5.15B
est: 4.57B (+12.6%)
|
7.10B
est: 5.03B (+41.1%)
|
5.25B
5.21B – 5.28B
+4.3% YoY
|
6.26B
6.13B – 6.39B
+19.3% YoY
|
7.42B
7.13B – 7.71B
+18.5% YoY
|
| EBIT |
1.73B
est: 762.39M (+127.0%)
|
2.88B
est: 4.55B (-36.8%)
|
4.03B
est: 2.89B (+39.5%)
|
2.56B
est: 3.21B (-20.1%)
|
855.14M
est: 2.02B (-57.8%)
|
1.89B
est: 1.61B (+16.9%)
|
3.15B
est: 3.36B (-6.3%)
|
-2.52B
est: 3.89B (-164.8%)
|
1.24B
est: 4.10B (-69.8%)
|
3.02B
est: 2.04B (+48.2%)
|
5.18B
est: 2.24B (+131.3%)
|
2.34B
2.32B – 2.35B
+4.3% YoY
|
2.79B
2.73B – 2.85B
+19.3% YoY
|
3.30B
3.18B – 3.43B
+18.5% YoY
|
| Net Income |
15.66M
est: 945.04M (-98.3%)
|
982.57M
est: 24.07B (-95.9%)
|
1.81B
est: 1.26B (+43.7%)
|
-457.92M
est: 3.40B (-113.5%)
|
523.08M
est: 6.25B (-91.6%)
|
241.47M
est: 3.07B (-92.1%)
|
2.55B
est: 412.56M (+516.9%)
|
-4.60B
est: 477.50M (-1,063.8%)
|
-2.21B
est: 503.15M (-539.6%)
|
-1.20B
est: -475.19M (-153.0%)
|
4.05B
est: 3.31B (+22.4%)
|
5.56B
4.87B – 5.95B
+67.9% YoY
|
6.54B
6.36B – 6.72B
+17.6% YoY
|
8.94B
8.57B – 9.25B
+36.8% YoY
|
| SGA |
1.54B
est: 1.84B (-16.4%)
|
3.23B
est: 8.93B (-63.9%)
|
3.30B
est: 9.20B (-64.1%)
|
2.84B
est: 7.00B (-59.4%)
|
1.79B
est: 8.65B (-79.2%)
|
2.62B
est: 6.61B (-60.4%)
|
3.45B
est: 10.29B (-66.4%)
|
4.99B
est: 11.91B (-58.1%)
|
5.26B
est: 12.55B (-58.1%)
|
4.29B
est: 5.43B (-21.0%)
|
5.41B
est: 5.97B (-9.4%)
|
6.22B
6.18B – 6.27B
+4.3% YoY
|
7.43B
7.27B – 7.58B
+19.3% YoY
|
8.80B
8.46B – 9.14B
+18.5% YoY
|
| EPS |
0.26
est: 10.27 (-97.5%)
|
11.90
est: 13.97 (-14.8%)
|
20.28
est: 17.06 (+18.9%)
|
-5.12
est: 9.13 (-156.0%)
|
5.84
est: 3.54 (+65.0%)
|
2.70
est: 13.09 (-79.4%)
|
28.40
est: 13.12 (+116.4%)
|
-51.28
est: -17.16 (-198.8%)
|
-24.56
est: -2.50 (-882.2%)
|
-13.21
est: -5.20 (-154.3%)
|
44.05
est: 36.00 (+22.4%)
|
58.80
52.94 – 64.66
+63.3% YoY
|
71.07
69.13 – 73.00
+20.9% YoY
|
96.85
93.16 – 100.54
+36.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.58M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 85.7K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 193.3K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 9.54M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 126.6K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 10.46M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 15.3K | 0.22% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 544.5K | 0.06% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 46.2K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 24.8K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arun Kumar Pillai | Founder & Non-Executive Chairperson | 90M | male |
| Badree Komandur | MD & Group Chief Executive Officer | 58M | male |
| Aditya Arun Kumar | Executive Director of Business Development & Director | 16M | male |
| Manjula Ramamurthy | Compliance Officer & Company Secretary | — | female |
| Nandini Matiyani | Executive Vice President of Human Resources | — | female |
| Sormistha Ghosh | Group General Counsel, Chief Risk Officer & Chief Sustainability Officer | — | female |
| Umesh Kale | Chief Quality Officer | — | male |
| V. S. Ramaraju | Chief Operating Officer | — | male |
| Vikesh Kumar | Group CFO | — | male |
| C. K. Sundar | Executive Vice President of Operations | — | male |
| Kevin Cook | Senior Vice President of Strides Pharma Inc. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STAR.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
